New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
24 09 2021
Historique:
received: 15 04 2021
accepted: 16 09 2021
revised: 03 09 2021
entrez: 25 9 2021
pubmed: 26 9 2021
medline: 4 2 2022
Statut: epublish

Résumé

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the presence of tyrosine kinase BCR-ABL1 fusion protein, which deregulate transcription and mRNA translation. Tyrosine kinase inhibitors (TKIs) are the first-choice treatment. However, resistance to TKIs remains a challenge to cure CML patients. Here, we reveal that the m

Identifiants

pubmed: 34561421
doi: 10.1038/s41419-021-04169-7
pii: 10.1038/s41419-021-04169-7
pmc: PMC8463696
doi:

Substances chimiques

MYC protein, human 0
PES1 protein, human 0
Proto-Oncogene Proteins c-myc 0
RNA, Messenger 0
RNA-Binding Proteins 0
Imatinib Mesylate 8A1O1M485B
N-methyladenosine CLE6G00625
METTL14 protein, human EC 2.1.1.-
Methyltransferases EC 2.1.1.-
METTL3 protein, human EC 2.1.1.62
Adenosine K72T3FS567

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

870

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : 21267
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : 21406
Organisme : Sapienza Università di Roma (Sapienza University of Rome)
ID : RM11916B4ADE223F

Informations de copyright

© 2021. The Author(s).

Références

Front Oncol. 2019 Apr 09;9:251
pubmed: 31024852
Mol Cell. 2004 Jul 2;15(1):17-29
pubmed: 15225545
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell Death Differ. 2005 Jun;12(6):534-40
pubmed: 15846378
Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9
pubmed: 29290617
Science. 2018 May 18;360(6390):800-805
pubmed: 29622725
Front Genet. 2016 May 06;7:75
pubmed: 27200084
Genes (Basel). 2019 Jan 08;10(1):
pubmed: 30626100
Bioinformatics. 2013 Jun 15;29(12):1565-7
pubmed: 23589649
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nature. 2017 Dec 7;552(7683):126-131
pubmed: 29186125
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Mol Cell Biol. 2007 May;27(10):3682-94
pubmed: 17353269
Nature. 2021 May;593(7860):597-601
pubmed: 33902106
N Engl J Med. 1999 Jul 15;341(3):164-72
pubmed: 10403855
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Protoc. 2006;1(1):241-5
pubmed: 17406239
Bioinformatics. 2015 Sep 1;31(17):2829-35
pubmed: 25957348
J Biol Chem. 2002 Nov 22;277(47):45347-55
pubmed: 12237316
Cell Death Dis. 2018 Jul 23;9(8):796
pubmed: 30038300
J Clin Invest. 2012 Aug;122(8):2857-70
pubmed: 22820289
Blood. 2009 Feb 19;113(8):1619-30
pubmed: 18827185
Nat Rev Mol Cell Biol. 2019 Oct;20(10):608-624
pubmed: 31520073
Blood. 2017 Mar 23;129(12):1595-1606
pubmed: 28159740
Genes Dev. 2020 Oct 1;34(19-20):1373-1391
pubmed: 32943573
Mol Cell. 2018 Jul 19;71(2):256-270.e10
pubmed: 30029004
Nat Med. 2017 Nov;23(11):1369-1376
pubmed: 28920958
Bioinformatics. 2013 Sep 1;29(17):2146-52
pubmed: 23821648
Cell. 2020 Jun 25;181(7):1582-1595.e18
pubmed: 32492408
Cancer Sci. 2009 Dec;100(12):2255-60
pubmed: 19764998
Int J Mol Sci. 2018 Aug 09;19(8):
pubmed: 30096915
Oncotarget. 2016 Sep 13;7(37):60155-60168
pubmed: 27517498
Cell Res. 2018 Sep;28(9):952-954
pubmed: 30006613
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9
pubmed: 16174746
Cell Rep. 2020 Dec 29;33(13):108598
pubmed: 33378672
Nat Cell Biol. 2019 Jun;21(6):700-709
pubmed: 31061465
Nat Rev Cancer. 2012 Jul 24;12(8):513-26
pubmed: 22825216
J Biol Chem. 2001 Mar 2;276(9):6656-65
pubmed: 11071894
Oncogene. 2007 Feb 22;26(8):1188-200
pubmed: 16936779
Nat Methods. 2009 Apr;6(4):275-7
pubmed: 19305406
Curr Opin Hematol. 2021 Mar 1;28(2):80-85
pubmed: 33337619
Nature. 2018 Sep;561(7724):556-560
pubmed: 30232453
Mol Cell. 2016 May 5;62(3):335-345
pubmed: 27117702

Auteurs

Zaira Ianniello (Z)

Department of Biology and Biotechnology 'Charles Darwin', Sapienza University of Rome, Rome, Italy.

Melissa Sorci (M)

Department of Biology and Biotechnology 'Charles Darwin', Sapienza University of Rome, Rome, Italy.

Lavinia Ceci Ginistrelli (L)

Department of Biology and Biotechnology 'Charles Darwin', Sapienza University of Rome, Rome, Italy.

Alessia Iaiza (A)

Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy.

Marcella Marchioni (M)

Institute of Biology, Molecular Medicine and Nanobiotechnology, CNR, Sapienza University of Rome, Rome, Italy.

Claudia Tito (C)

Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy.

Ernestina Capuano (E)

Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy.

Silvia Masciarelli (S)

Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy.
Histology and Embryology Section, Department of Life Science and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Tiziana Ottone (T)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Fondazione Santa Lucia, Laboratorio di Neuro-Oncoematologia, Rome, Italy.

Cristina Attrotto (C)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Manuela Rizzo (M)

Fondazione Policlinico Tor Vergata, Rome, Italy.

Luca Franceschini (L)

Fondazione Policlinico Tor Vergata, Rome, Italy.

Stefano de Pretis (S)

Center for Genomic Science, Fondazione Istituto Italiano di Tecnologia, Milan, Italy.

Maria Teresa Voso (MT)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Fondazione Santa Lucia, Laboratorio di Neuro-Oncoematologia, Rome, Italy.

Mattia Pelizzola (M)

Center for Genomic Science, Fondazione Istituto Italiano di Tecnologia, Milan, Italy.

Francesco Fazi (F)

Department of Anatomical, Histological, Forensic & Orthopedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy. francesco.fazi@uniroma1.it.
Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy. francesco.fazi@uniroma1.it.

Alessandro Fatica (A)

Department of Biology and Biotechnology 'Charles Darwin', Sapienza University of Rome, Rome, Italy. alessandro.fatica@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH